Non-motor symptoms of PD revealed in mice with reduced vesicular storage Tonya Taylor MSP Symposium May 29, 2009.

Slides:



Advertisements
Similar presentations
David Krantz MD, PhD Department of Psychiatry & Biobehavrioal Sciences
Advertisements

An Overview of Conventional and Experimental Treatments
Parkinson’s Disease Shirley H. Wray, M.D., Ph.D., Professor of Neurology, Harvard Medical School Director, Unit for Neurovisual Disorders Massachusetts.
James Parkinson Born in 1755; died Lived entire life in London. Political reformer Paleontologist Physician.
PHL 437/Pharmacogenomics Fourth Lecture (Parkinson’s disease) By Abdelkader Ashour, Ph.D. Phone:
Parkinson’s disease Interventions Whitney Mundy Dr. Davis.
A preliminary model for the role of the basal ganglia in natural motor control and motor programming MURI Meeting, June 4th, 2002 Steve Massaquoi, Zhi-Hong.
Parkinson’s Disease Pathology 430/826 The Molecular Basis of Disease Neurological Genetics 9 th March 2015 Dr. John Rossiter
Paul Short, Ph.D. The Parkinson’s Coach NEUROPSYCHOLOGY OF PARKINSON’S COMMUNICATION PROBLEMS.
Parkinson’s Disease First described as the ‘shaking palsy’ by James Parkinson, this neurodegenerative plagues nearly 1 million Americans who have been.
Is it a neurodegenerative brain disorder that progresses slowly in most people.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Corso di Terapia genica Prof.ssa Saggio a.a. 2011/2012 LRRK2-FAMILIAR PARKINSON DISEASE: POSSIBLE APPROACH OF GENE THERAPY Cesario Claudia Giusti Valentina.
NEUROLOGICAL DISORDERS. Dementia  A degenerative syndrome characterized by deficits in memory, language, and mood.  The most common form: Alzheimer’s.
AMPAKINE Compounds for the Treatment of Rett Syndrome
Current Topics in Neuropsych Research June 28, 2011.
Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative.
SYMPTOM CONTROL IN ADVANCED PARKINSON’S DISEASE Vicky Travers PDNSUHMBT April 2012.
Duodenal Levodopa Treatment in advanced Parkinson’s Disease
Parkinson’s Plus By: Glen Estrosos.
Neuroscience 1 Pause for thought: Probably 100 million neurones fire during skilled movements.
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
Motor Response Complications and Cycline-Dependent Kinase 5 (Cdk5) Neuroadaptations in an Animal Model of Parkinson’s Disease Heather Minkel Dr. Justin.
BY: MACKENZIE SOARES ALYSSA MEDIEROS STEPHANIE GARDNER Parkinson's Disease.
Innovations in Parkinson’s Diagnosis & Treatment: A Personal Story Dr. Kenneth E. Keirstead Excellence in Aging Care Symposium September 25-27, 2013.
Parkinson’s disease – diagnosis in the bowel? David Hilton Department of Cellular and Anatomical Pathology, Derriford Hospital, Plymouth.
Treatment of Parkinson Disease David Tran, 2013 Mercer University PharmD Candidate.
Is It Essential Tremor or a Parkinsonian Syndrome? Diagnostic Considerations in Primary Care Faculty Tanya Simuni, MD Director, Parkinson's Disease and.
Mostly Parkinson’s disease but also few other movement disorders due to diseases of the basal ganglia.
Neurotransmitters: Catecholamines & Acetylcholine Chapters 5 & 6 Catecholamines  Dopamine  Norepinephrine  Epinephrine Acetylcholine Serotonin Glutamate.
Temporal Enhancement of Motor Control in Parkinson’s Disease patients Marta Bieńkiewicz PhD Student Queen’s University Belfast.
Group 5.  100+  Precise roles not known  3 categories.
NEUROLOGICAL DISORDERS. Dementia  A degenerative syndrome characterized by deficits in memory, language, and mood.  The most common form: Alzheimer’s.
 Parkinson’s Disease (PD) -progressive neurodegenerative disease affecting motor ability -third most common neurologic disorder of older adults.
Current Topics in Neuropsych Research June 28, 2011.
Mitochondria in the etiology and pathogenesis of Parkinson's disease
Optogenetics: What you see is what you think
Parkinson's disease Carlo Varas. Definition progressive disorder of the nervous system that affects movement. tremor may be the most well-known sign of.
By: Alejandro Navarro and Andrea Ors. Content Introduction What is Parkinson's disease? What causes the disease? History Main symptoms Treatment Statistics.
Neurological Disorders
second most common neurodegenerative disorder progressive loss of muscle control trembling of the limbs and head while at rest stiffness, slowness, and.
Odor and Spatial Working Memory in an Environmentally-Induced Animal Model of Parkinsonism Christina M. Parr & Aileen Bailey, Ph.D. Department of Psychology,
By Katelyn Chaimson and Sean Guyot
Α-synuclein transgenic mouse models of Parkinson’s disease Michelle Maurer December 2015.
Parkinson's disease By Colby Allen. symptoms Mild to major tremors. Rigidity or joint stiffness Bradykinesia or slowness of movement Postural instability.
Wang Chung Han. INTRODUCTION Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder resulting from a CAG expansion in the huntingtin.
 Parkinson Disease (PD) is a progressive disorder of the central nervous system that often impairs the sufferer's motor skills, speech, and other functions.
Pathogenesis and pathology of parkinsonism
Dopaminergic Animal Models of RLS William Ondo, MD Department of Neurology, Baylor College of Medicine Houston, TX
Reflections on animal models of neurological disorders Marie-Francoise Chesselet UCLA
P = 0.08 Preliminary Characterization of Sleep-Wake Behavior and Locomotor Activity in the VMAT2-Deficient Mouse Model of Parkinson’s Disease Introduction.
PARKINSON’S DISEASE CHAMINDA UNANTENNE RN,MS,MSN.
Basal ganglia D.Nimer D.Rania Gabr D.Safaa D.Elsherbiny.
“HEALTH IS THE BEST” In the name of God. WHAT IS IT? Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Sapana Shinde, Aaron Ripley, Dr. Sok Kean Khoo MicroRNA expression studies in rotenone- induced cellular model for Parkinson’s disease Department of Cell.
Parkinson’s Disease.
Why does Parkinson’s Disease occur?
Drugs for Parkinson’s Disease
Parkinson's disease KRZYSZTOF NICPOŃ.
The Effects of 6-hydroxydopamine (6-OHDA) and Neuronal Nitric Oxide Synthase Inhibitor ( nNOSI) on Ability of Zebrafish to recover from parkinson’s disease-like.
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
Parkinson's disease Parkinson's disease (PD) is the second-most common
Justin Hayase MSTAR Presentation Guo Lab July 23,2009
Long Term Effects of Concussions
Justin Hayase MSTAR Presentation Guo Lab July 23,2009
Neurodegenerative diseases
Transgenic expression of mCREB or CREB produces opposite effects in the learned helplessness model of depression. Transgenic expression of mCREB or CREB.
HOW DOES EXPERIENCE AFFECT BEHAVIOUR AND MENTAL PROCESSES?
Presentation transcript:

Non-motor symptoms of PD revealed in mice with reduced vesicular storage Tonya Taylor MSP Symposium May 29, 2009

Overview of Parkinson’s Disease 2 nd most common neurodegenerative disorder Characterized by degeneration of DA neurons in the SNpc, subsequent loss of DA in the striatum, and presence of Lewy bodies Caused by genetic and environmental factors Tremor, rigidity, postural instability, bradykinesia Anosmia, sleep disturbances, depression, GI dysfunction

Characterization of VMAT2 LO mice Caudle, et al J. Neurosci 2007

VMAT2-deficient mice display widespread reductions in monoamines at months of age Taylor, et al J. Neurosci in press

VMAT2-deficient animals display reduced TH/TrpH expression and neurodegeneration at 24 months of age

Hypothesis: Reduced monoamine storage results in altered neurotransmission leading to the development of symptoms associated with PD

VMAT2 LO animals display progressive deficits in olfactory discrimination Taylor, et al J. Neurosci in press

VMAT2 LO animals display normal circadian activity but a premature shortened latency to behavioral signs of sleep Taylor, et al J. Neurosci in press

VMAT2 LO mice display altered gastric motility Taylor, et al J. Neurosci in press

VMAT2 LO animals display an anxiety-like and a progressive depressive-like phenotype Taylor, et al J. Neurosci in press 4-6 months12-15 months FST TST

VMAT2 LO mice exhibit motor deficits at older ages

Conclusions and Future Directions Reduced vesicular storage of monoamines reproduces many of the non-motor symptoms associated with PD – at advanced ages, reproduces motor phenotype Potential model for therapeutic intervention for non-motor symptoms – Antidepressant therapy? – Monoamine precursors?

Acknowledgements Miller Lab Dr. Gary Miller Kennie Shepherd, PhD Jodi Watson, BSN, MS Minzheng Wang, MD Yingjie Li, MD Danielle Dean, MS Stephen Hasak, MPH David Kopp, MPH Dana Annerino Brian Wojeck Weinshenker Lab Dr. David Weinshenker Jesse Schank, PhD Heather Mitchell Greene Lab Dr. James Greene AliReza Noorian, MD Iuvone Lab Dr. P. Michael Iuvone Nikita Pozdeyev, PhD Chad Jackson University of Washington W. Michael Caudle, PhD Committee Members Dr. James Greene Dr. Jason Hansen Dr. Yoland Smith Dr. David Weinshenker Funding NRSA F31 ES Emory Graduate Diversity Fellowship